Journal of Clinical Oncology, Vol 5, 1890-1899, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies

AA Epenetos, AJ Munro, S Stewart, R Rampling, HE Lambert, CG McKenzie, P Soutter, A Rahemtulla, G Hooker and GB Sivolapenko
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

Twenty-four patients with persistent epithelial ovarian cancer after chemotherapy with or without external beam irradiation, were treated with intraperitoneally administered 131I-labeled monoclonal antibodies HMFG1, HMFG2, AUA1, H17E2, directed against tumor-associated antigens. Acute side effects were mild abdominal pain, pyrexia, diarrhea, and moderate reversible pancytopenia. One patient developed a subphrenic abscess requiring surgical drainage. Eight patients with large volume disease, ie, greater than 2 cm tumor diameter, did not respond to antibody-guided irradiation and died of progressive disease within 9 months of treatment. Sixteen patients had small-volume (less than 2 cm) disease at the time of treatment with radiolabeled antibody. Seven patients failed to respond, and of nine initial responders, four patients remain alive and free from disease 6 months to 3 years from treatment. Analysis of the data on relapse indicated that doses greater than 140 mCi were more effective than lower doses. We conclude that the intraperitoneal administration of 140 mCi or more of 131I-labeled tumor- associated monoclonal antibodies represents a new and potentially effective form of therapy for patients with small-volume stage III ovarian cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. C. Chauhan, N. Vinayek, D. M. Maher, M. C. Bell, K. A. Dunham, M. D. Koch, Y. Lio, and M. Jaggi Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer: Antigens for Multi-targeted Antibody-guided Therapy J. Histochem. Cytochem., August 1, 2007; 55(8): 867 - 875. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, C. M. Richman, H. Albrecht, P. A. Burke, A. Natarajan, A. Yuan, J. P. Gregg, R.T. O'Donnell, and G. L. DeNardo Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer Clin. Cancer Res., October 1, 2005; 11(19): 7187s - 7194s. [Abstract] [Full Text] [PDF]

				P. E. Borchardt, R. R. Yuan, M. Miederer, M. R. McDevitt, and D. A. Scheinberg Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer Cancer Res., August 15, 2003; 63(16): 5084 - 5090. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]

				M. G. Rosenblum, C. F. Verschraegen, J. L. Murray, A. P. Kudelka, J. Gano, L. Cheung, and J. J. Kavanagh Phase I Study of 90Y-labeled B72.3 Intraperitoneal Administration in Patients with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity Clin. Cancer Res., May 1, 1999; 5(5): 953 - 961. [Abstract] [Full Text] [PDF]

				R. O. Dillman Monoclonal Antibodies for Treating Cancer Ann Intern Med, October 1, 1989; 111(7): 592 - 603. [Abstract] [PDF]